Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | PTPRC | P08575 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7261858 | 0.82 | KDM4E (0.34) | SLC6A3SLC6A4KDM4EALDH1A1 | |
| SCHEMBL10779115 | 0.79 | CETP (0.33) | PTPRCKDM4ELMNATSHR | |
| SCHEMBL29069277 | 0.78 | — | — | |
| SCHEMBL29069303 | 0.77 | — | — | |
| SCHEMBL16180647 | 0.74 | — | — | |
| SCHEMBL9680789 | 0.74 | — | — | |
| SCHEMBL28868123 | 0.74 | — | — | |
| SCHEMBL29069312 | 0.74 | — | — | |
| SCHEMBL9679867 | 0.72 | — | — | |
| SCHEMBL28868083 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1353925-A2 | PROCESSES FOR LARGE SCALE PRODUCTION OF TETRAPYRROLES | Miravant Pharmaceuticals, Inc. (US) | 2003-10-22 | — | — | EP | claimed |
| WO-2002083686-A2 | PROCESSES FOR LARGE SCALE PRODUCTION OF TETRAPYRROLES | MIRAVANT PHARMACEUTICALS, INC. (US) | 2002-10-24 | — | — | WO | claimed |
| US-6462192-B2 | SUCH AS MESO-FORMYL PORPHYRINS, MESO-ACRYLATE PORPHYRINS, PURPURINS AND BENZOCHLORINS. IN PARTICULAR, TIN ETHYL ETIOPURPURIN (SNET2) AND THE INTERMEDIATES NECESSARY FOR ITS PRODUCTION WITHOUT CHROMATOGRAPHY | MIRAVANT PHARMACEUTICALS, INC. | 2002-10-08 | — | — | US | claimed |
| US-20020137924-A1 | Processes for large scale production of tetrapyrroles | MIRAVANT PHARMACEUTICALS, INC. | 2002-09-26 | — | — | US | claimed |
| EP-1353925-A2 | PROCESSES FOR LARGE SCALE PRODUCTION OF TETRAPYRROLES | Miravant Pharmaceuticals, Inc. (US) | 2003-10-22 | — | — | EP | disclosed |
| WO-2002083686-A2 | PROCESSES FOR LARGE SCALE PRODUCTION OF TETRAPYRROLES | MIRAVANT PHARMACEUTICALS, INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| US-6462192-B2 | SUCH AS MESO-FORMYL PORPHYRINS, MESO-ACRYLATE PORPHYRINS, PURPURINS AND BENZOCHLORINS. IN PARTICULAR, TIN ETHYL ETIOPURPURIN (SNET2) AND THE INTERMEDIATES NECESSARY FOR ITS PRODUCTION WITHOUT CHROMATOGRAPHY | MIRAVANT PHARMACEUTICALS, INC. | 2002-10-08 | — | — | US | disclosed |
| US-20020137924-A1 | Processes for large scale production of tetrapyrroles | MIRAVANT PHARMACEUTICALS, INC. | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137924-A1 | Processes for large scale production of tetrapyrroles | SNU13, NPEPPS, ESYT2 | SLC6A3 1442/4885SLC6A4 1322/4885PTPRC 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.